Sun Pharmaceutical Industries appoints Kirti Ganorkar as Managing Director, effective September 1, 2025. Learn about this major leadership change and what it means for India’s largest drugmaker.
In a strategic leadership realignment, Sun Pharma has announced the appointment of Kirti Ganorkar as its Managing Director, starting from September 1, 2025. He succeeds Dilip Shanghvi, who will now serve as Executive Chairman, maintaining oversight on the company’s strategic direction and specialty.
- Protected: Big update in Spot Gold [13-06-2025]
- Reliance Sells 3.6% Stake in Asian Paints to SBI MF for $900 Million
- When will MCX Silver Rise?
- Israel-Iran conflict: Crude oil prices jump over 13%; Brent crude oil above $73 per barrel
- Israel Attacks Iran LIVE: Iran Deploys Over 100 Drones
Sun Pharma Welcomes New Leadership
Sun Pharmaceutical Industries, India’s biggest drug company, has announced an exciting change in its leadership team. Starting September 1, 2025, Kirti Ganorkar will take over as the new Managing Director (MD), succeeding the company’s founder, Dilip Shanghvi. This move is part of Sun Pharma’s plan to ensure smooth leadership transitions and continued growth.
Who is Kirti Ganorkar?
Kirti Ganorkar is no stranger to Sun Pharma. He joined the company in 1996 and has been leading its India business since June 2019. With a background in chemical engineering and an MBA, Kirti has played a key role in growing Sun Pharma’s presence in markets like Japan and Europe. He has also worked on major projects in the U.S., helping the company bring new generic medicines to market. His experience and leadership make him a strong choice to guide Sun Pharma into the future.
What Happens to Dilip Shanghvi?
Dilip Shanghvi, the current Managing Director and founder of Sun Pharma, will step into the role of Executive Chairman. This means he will continue to lead the company’s board and provide strategic guidance. Shanghvi has expressed confidence in Kirti’s ability to lead, saying, “Kirti has shown strong leadership in many roles at Sun Pharma. I believe he will take the company to new heights while keeping our core values strong.”
A Bright Future for Sun Pharma
Kirti Ganorkar is excited about his new role. He said, “Sun Pharma is in a great position for growth, and I’m ready to build on the foundation laid by Mr. Shanghvi.” With all business operations reporting to him, Kirti will oversee the company’s global efforts. His appointment is still subject to approval by shareholders at the upcoming annual general meeting (AGM).
Other Leadership Changes
Sun Pharma also announced other updates to its leadership team. Richard Ascroft will take over as CEO of the North America business, replacing Abhay Gandhi. Additionally, Shanghvi’s son, Aalok Shanghvi, was recently promoted to Chief Operating Officer, and his daughter, Vidhi Shanghvi, was appointed as a Whole-time Director. These changes show Sun Pharma’s focus on nurturing talent from within the company.
Why This Matters
This leadership transition is a big moment for Sun Pharma, which has a market value of over ₹52,000 crore. By choosing Kirti Ganorkar, a long-time insider, the company is ensuring stability while preparing for future growth. Fans of Sun Pharma can look forward to seeing how Kirti’s leadership shapes the company’s journey in the global pharmaceutical industry.
